Profitability in 2026 will be largely defined by the September 24, 2026 launch of CONTROL Resonant, with the period framed as an investment phase.

Near-term margins are pressured by marketing and development spend for Resonant, even as executives emphasize the strategic, year-long investment ahead of launch.

Executives underline Remedy’s focus on story-driven single-player experiences and position Resonant as the flagship project, with plans to accelerate marketing in Q3 ahead of release.

The company is pursuing global localization and potential platform expansions beyond traditional PC and consoles, following initial Control porting success.

Remedy reports Alan Wake 2 has surpassed 3 million in lifetime sales through the first half of 2026, up from over 2 million by early 2025.

Sales for the 2019 title Control have picked up in Q2 due to ongoing Resonant promotion, while Remedy’s overall portfolio remains robust as Alan Wake 2 crosses the 3 million mark and Control endures into its seventh year.

Management says Resonant is tracking well against comparable launches and expects a less crowded release window to aid positioning.

Revenue declined in the period due to a tough year-ago comparison from Firebreak and intensified Resonant marketing ahead of its launch.

The dip is attributed to the earlier Firebreak launch and heavier promotional activity targeting Resonant.

Remedy remains financially cautiously viable, with no major layoffs since 2020, and future prospects hinging on Resonant’s performance and portfolio momentum.

Leadership notes the catalog as a backbone while Resonant nears production readiness, with marketing stepping up into Q3 and confidence in Resonant’s potential.

Analysts and investors reacted positively to the launch outlook, lifting Remedy’s stock in premarket trading toward the year’s high as the market bets on Resonant as a catalyst.